Abstract
To determine whether the chemotherapy resistance of non-small cell lung cancer could be modified by oral dexverapamil, the D-isomer of verapamil, 54 patients were entered into a randomised phase II study of oral dexverapamil plus chemotherapy (vindesine/etoposide) (arm B) versus chemotherapy (arm A) alone in January 1994. Chemotherapy consisted of intravenous vindesine 3 mg/m2 bolus on days one and five and etoposide 140 mg/m2 on days two and four. Dexverapamil was given for six days, 1500 mg a day divided into six doses of 250 mg every four hours starting 24 h prior to chemotherapy. According to the individual tolerability, the single dose could be increased up to a maximum of 400 mg. Cycles were repeated 3 weekly up to four courses. At this stage of the analysis, 34 patients (18 in arm A and 16 in arm B) are evaluable for toxicity and response. Cardiovascular side effects were more marked in the patient group with dexverapamil. On average, the dose of dexverapamil was 1800 mg a day. There were 5 partial remissions (31.3%) and 9 no changes (56.3%) in the group with dexverapamil as opposed to 2 partial remissions (11.1%) and 6 no changes (33.3%) in the group without dexverapamil. As far as the preliminary results show, the addition of dexverapamil to vindesine/etoposide chemotherapy in this study seems to be associated with improved outcome.
Similar content being viewed by others
References
Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M (1985) The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109: 210–217
Gloor H O, Urthaler F (1983) Differential effect of verapamil isomers on sinus node and AV junctional region. Am J Physiol 244: H80
Gruber A, Peterson C, Reizenstein P (1988) D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leucaemic cells in vitro. Int J Cancer 41: 224–226
Kaufman A, Serur J R (1976) Optical isomers of verapamil on canine heart. Prevention of ventricular fibrillation induced by coronary artery occlusion, impaired atrioventricular conduction and negative inotropic and bronchotropic effects. Naunyn Schmiedebergs Arch Pharmacol 292: 21–27
Keilhauer G, Emling F, Raschack M The use of R-verapamil is superior to racemic verapamil in breaking multidrug resistance of malignant cells. Proc of the 80th Annual Meeting of the American Assoc for Cancer Research Vol 30: 503
Millward M J, Cantwell BMJ, Munro N C, Robinson A, Corris P A (1993) Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomized study. Br J Cancer 67: 1031–1035
Pommerenke E W, Mattern J, Traugott U, Volm M (1991) Durchbrechung der Multidrug-Resistenz mit (R)-Verapamil in vitro und in vivo. Drug Res 41 (II) 855–858
Rosenthal S A, Curran W J (1990) The significance of histology in non-small cell lung cancer. Cancer Treat Rev 17: 409–425
Tsuruo T, Tida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gatzemeier, U., Schneider, A. & Pawel, J.v. Randomised trial of vindesine and etoposide ± dexverapamil in advanced non-small cell lung cancer: First results. J Cancer Res Clin Oncol 121 (Suppl 3), R17–R20 (1995). https://doi.org/10.1007/BF02351066
Issue Date:
DOI: https://doi.org/10.1007/BF02351066